Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509737 | 0.91 | RAB9A (0.58) | RAB9APTGS2KDM4ENOTUMMAPT | |
| SCHEMBL11765171 | 0.87 | RAB9A (0.62) | RAB9APTGS2KDM4ENOTUMMAPT | |
| SCHEMBL11763853 | 0.84 | RAB9A (0.70) | RAB9APTGS2KDM4EMAPTALDH1A1 | |
| SCHEMBL6302056 | 0.83 | FLT3 (0.53) | RAB9AFLT3GSK3BKDM4ENOTUM | |
| SCHEMBL8110243 | 0.75 | ALDH1A1 (0.52) | RAB9AFLT3GSK3BPTGS2KDM4E | |
| SCHEMBL11443525 | 0.75 | KDM4E (0.56) | RAB9APTGS2KDM4EMAPTALDH1A1 | |
| SCHEMBL6304987 | 0.75 | RAB9A (0.49) | RAB9APTGS2KDM4ENOTUMALDH1A1 | |
| SCHEMBL11763450 | 0.74 | RAB9A (0.75) | RAB9APTGS2KDM4ENOTUMMAPT | |
| SCHEMBL11763669 | 0.73 | RAB9A (0.47) | RAB9APTGS2KDM4EMAPTCA12 | |
| SCHEMBL11762851 | 0.73 | KDM4E (0.57) | RAB9APTGS2KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | claimed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | claimed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | claimed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-6852740-B2 | Pyrazole derivatives as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6503930-B1 | Treating cytokine-mediated diseases, such as inflammation | G.D. SEARLE & COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | MAPK1, MAPK3, MAP3K1 | RAB9A 1009/4885FLT3 520/4885GSK3B 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.